1. Home
  2. NTWK vs NXTC Comparison

NTWK vs NXTC Comparison

Compare NTWK & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NetSol Technologies Inc.

NTWK

NetSol Technologies Inc.

HOLD

Current Price

$3.46

Market Cap

39.7M

Sector

Technology

ML Signal

HOLD

Logo NextCure Inc.

NXTC

NextCure Inc.

HOLD

Current Price

$12.77

Market Cap

35.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTWK
NXTC
Founded
1997
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.7M
35.9M
IPO Year
1997
2019

Fundamental Metrics

Financial Performance
Metric
NTWK
NXTC
Price
$3.46
$12.77
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$23.00
AVG Volume (30 Days)
26.3K
33.3K
Earning Date
05-13-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
316.67
N/A
EPS
N/A
N/A
Revenue
$73,088,687.00
$22,378,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
13.40
N/A
52 Week Low
$2.26
$0.31
52 Week High
$5.75
$15.74

Technical Indicators

Market Signals
Indicator
NTWK
NXTC
Relative Strength Index (RSI) 50.01 63.93
Support Level $2.89 $10.73
Resistance Level $3.70 $14.01
Average True Range (ATR) 0.16 1.08
MACD -0.01 0.30
Stochastic Oscillator 56.29 86.45

Price Performance

Historical Comparison
NTWK
NXTC

About NTWK NetSol Technologies Inc.

NETSOL Technologies Inc is an information technology and enterprise software solutions provider to original equipment manufacturers (OEMs), dealerships, and financial institutions to sell, finance, and lease assets. The firm's products include Transcend Retail, Transcend Finance, Transcend Marketplace, Transcend Consultancy, and Transcend AI Labs, catering to its customers in the different stages of how assets are sold, financed, and leased. Its primary sources of revenue are licensing, subscriptions, modification, enhancement, and support of its suite of financial applications offered to businesses in the finance and leasing space, as well as automotive digital retail. The company has three reportable segments: Asia-Pacific, its key revenue-generating market, North America, and Europe.

About NXTC NextCure Inc.

NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Share on Social Networks: